# US 2010/0168381 A1 · Conjugates of membrane translocating agents and pharmaceutically active agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168381 A1
- Document ID: US20100168381A1
- Status: Published application
- Kind: A1
- Application number: 12/645,922
- Filed: 2009-12-23
- Published: 2010-07-01
- Earliest claimed: 1999-09-27
- Assignees: Merrion Research III Limited
- Inventors: Daniel O'Mahony; Imelda Lambkin; Clemencia Pinilla; Richard Houghten
- Web page: https://patentgrep.com/patent/US20100168381A1

## CPC

- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/5138: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 38/28: Insulins
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 14/50: Fibroblast growth factor [FGF]
- C07K 14/665: derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

## Claims

### Claim 1

A composition comprising a translocating peptide, wherein said translocating peptide is selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 4 contiguous amino acids of said transport peptide, wherein said transport peptide is selected from the group consisting of an L-peptide, a d-peptide, and a retroinverted peptide and wherein said L-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS:4-13 and 15-24, wherein said d-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS.60-82, and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS.85-105.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the transport peptide is partially or completely cyclic.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the transport active fragment is partially or completely cyclic.

### Claim 4 (depends on 1)

The composition of claim 1, wherein the transport peptide is completely cyclic.

### Claim 5 (depends on 1)

The composition of claim 1, wherein the transport-active fragment is completely cyclic.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the transport-active fragment is at least 6 contiguous amino acids of said transport peptide.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the transport-active fragment is at least 8 contiguous amino acids of said transport peptide.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the carboxyl end group of the translocating peptide has been modified to create an amide group.

### Claim 9

A chimeric polypeptide comprising (A) a translocating peptide selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 4 contiguous amino acids of said transport peptide, wherein said transport peptide is selected from the group consisting of an L-peptide, a d-peptide, and a retroinverted peptide and wherein said L-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS:4-13 and 15-24, wherein said d-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS.60-82, and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS.85-105, (B) a translocatable peptide, and (C) an amino acid linker sequence that directly links the tranlocating peptide to the translocatable peptide, wherein said translocatable peptide is between 3 and 200 amino acids, and wherein said amino acid linker sequence is between 1 and 20 amino acids.

### Claim 10 (depends on 9)

The chimeric peptide of claim 9 wherein said translocatable peptide is between 3 and 30 amino acids.

### Claim 11 (depends on 9)

The chimeric peptide of claim 9 wherein the translocatable peptide is an opiod peptide.

### Claim 12 (depends on 9)

The chimeric peptide of claim 9 wherein said linker sequence is not more than 7 amino acids.

### Claim 13

A composition comprising a translocating peptide, said translocating peptide selected from the group consisting of a transport peptide and an extended peptide comprising said transport peptide, wherein said transport peptide is selected from the group consisting of an L-peptide, a d-peptide, and a retroinverted peptide and wherein said L-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS:4-13 and 15-24, wherein said d-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS.60-82, and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS.85-105, and wherein said transport peptide is partially or completely cyclic.

### Claim 14

A composition comprising a translocating peptide, said translocating peptide selected from the group consisting of a transport peptide, an extended peptide comprising said transport peptide, and a transport-active fragment of at least 9 contiguous amino acids of said transport peptide, wherein said transport peptide is selected from the group consisting of an L-peptide, a d-peptide, and a retroinverted peptide and wherein said L-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS:4-13 and 15-24, wherein said d-peptide has an amino acid sequence selected from the group consisting of SEQ ID NOS. 60-82, and wherein the retroinverted peptide comprises a d-form amino acid sequence selected from the group consisting of a peptide of SEQ ID NOS. 85-105, and wherein said transport peptide is partially or completely cyclic.
